|

Sintilimab+Anlotinib+Pemetrexed+Cisplatin Clinical Trials

1 actively recruiting trial

Also known as: S+A+PC

Pipeline

Phase 2: 1

Top Sponsors

  • Cancer Institute and Hospital, Chinese Academy of Medical Sciences1

Indications

  • Mesothelioma Malignant Advanced1
  • Mesothelioma, Malignant Pleural1
  • Mesothelioma, Malignant1
  • Lung Cancer1
  • Cancer1

Other1 trial

First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.